Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00955773 · ClinicalTrials.gov registry record · Phase 1
A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT00955773 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 64 participants.
The verdict
NCT00955773, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the recommended dose and regimen for the orally administered MEK inhibitor GSK1120212 dosed in combination with everolimus in subjects with solid tumors. The escalation part of the study will determine the MTD. The combination will be further explored in the expansion part in subjects with metastatic pancreatic cancer. In addition, subjects with KRAS mutant non-small cell lung cancer will be enrolled.
Interventions
- DRUG GSK1120212 plus everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2009-08-17 |
| Est. Completion | 2011-11-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00955773
The ClinicalTrials.gov registry entry for NCT00955773 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK1120212 plus everolimus is the first listed.
NCT00955773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00955773 about?
NCT00955773 is a clinical study titled "A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects". The purpose of this study is to determine the recommended dose and regimen for the orally administered MEK inhibitor GSK1120212 dosed in combination with everolimus in subjects with solid tumors. The escalation part of the study will determine the MTD. The combination will be further explored in the...
What is the current status of trial NCT00955773?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2009-08-17. Estimated completion is 2011-11-08.
What interventions are being tested in trial NCT00955773?
The interventions under investigation include: GSK1120212 plus everolimus (DRUG).
Who is sponsoring clinical trial NCT00955773?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.